Latest News
BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript
BNTX earnings call for the period ending September 30, 2024.
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
This drugmaker's lead candidate could become a top-selling cancer therapy.
Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) sent shares surging up to $61.71
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
/CNW/ - Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 variant adapted COMIRNATY®...
Here's Why Everyone's Talking About Summit Therapeutics
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.
Should You Buy Novavax Stock After This Regulatory Win?
The biotech continues to earn important wins, but is it enough?
Analysts Predict Strong Growth for Cancer Vaccine Market: Key Biotech Stocks to Consider
Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – Back in 2022, Nature published an article titled Cancer vaccines:...
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19.
Why Pfizer Stock Slumped on Friday
Investors were cautiously pessimistic about the latest news coming out of the company's lab.
BioNTech Se (BNTX) Q2 2024 Earnings Call Transcript
BNTX earnings call for the period ending June 30, 2024.
BioNTech (BNTX), a prominent player in the biotechnology sector, has announced its financial results for the second quarter of 2024, showcasing a mix of significant achievements and challenges. This quarter has been pivotal for BioNTech as it continues to navigate the evolving landscape of the biotechnology industry. Key Insights from...
Even if you can see it coming, you’re never going to time it just right
Biotech Innovations Drive Pancreatic Cancer Treatment: Market Expected to Reach $7.4 Billion by 2032
USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins Medicine, up to 80% of patients are...
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
/CNW/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by...
Advancements in Cancer Therapeutics: What to Expect from the Upcoming 2024 Oncology Conference
USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in Antibody-Drug Conjugates (ADCs). From...
Why Vaccine Stocks Rallied This Week
A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?
Moderna has been locked in a legal battle with Pfizer-BioNTech over their COVID shot Comirnaty after suing them in 2022 for allegedly copying its mRNA technology
BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript
BNTX earnings call for the period ending March 31, 2024.
BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript
BNTX earnings call for the period ending December 31, 2023.
BioNTech posted revenues of €3.819-billion, down by more than three-quarters compared to 2022, and net profit of €930.3-million, 90% lower than a year earlier
BNTX DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 12, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, both dates inclusive (the “Class...
BNTX DEADLINE TOMORROW: ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 11, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, both dates inclusive (the “Class...
BNTX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 10, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, both dates inclusive (the “Class...
BNTX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 09, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, both dates inclusive (the “Class...